Q2 2026 results exceeded expectations, with adjusted EPS of $2.51 and strong performance across Medicaid, Medicare, and Marketplace segments. Full-year EPS guidance was raised to over $4.80, driven by improved margins and operational efficiencies. Margin restoration and AI-driven transformation remain key priorities.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.